NeuroSearch Presents Additional Data From the MermaiHD Study With Huntexil(R) at the 5th Annual CHDI Conference on Huntington's
February 10 2010 - 10:40AM
Today, at the 5th Annual CHDI Conference on Huntington's disease,
held 8 to 11 February in Palm Springs, California, NeuroSearch
(NEUR.CO) presented the results from the MermaiHD study, a Phase
III study with Huntexil(r) (pridopidine) for the treatment of
Huntington's disease. Top-line results from the study were
announced on 3 February 2010 (Announcement no. 01-10),
Presenting as the featured speaker at the conference, Dr. Joakim
Tedroff, Head of Clinical Science at NeuroSearch on Wednesday 10
February, 4pm to 5pm PDT (Thursday, 1am to 2am CET) presented the
study results, including the following:
* Efficacy - Results from the MermaiHD study demonstrate that
six months' (26 weeks) treatment with Huntexil(R) (45 mg BID), in
Huntington's patients significantly improves both voluntary
movement control, as measured on the primary endpoint, the mMS, and
also a broader range of voluntary and involuntary motor symptoms,
including dystonia and eye movements. Measured in both the ITT
(Intention to treat) and the PP (per protocol, 82% of patients)
populations, the improvements seen were highly statistically
significant, and thereby the results in the PP population fully
confirm the ITT analysis :
Motor scale; Significance level for the PP population; Significance level
for the ITT population;
Modified Motor Score, mMS; p